Saturday 17 October 2026
Export MSLE’s income statement to Excel — free account
Satellos Bioscience Inc.
MSLE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 42.5% and free cash flow fell 65.7%, each against the same quarter a year earlier.
6.46
0.38
−5.56%
Follow MSLE
Satellos Bioscience Inc. (MSLE) P/E ratio
Satellos Bioscience Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2021 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTX Nkarta, Inc. compare | n/m |
| ALXO ALX Oncology Holdings Inc. compare | n/m |
| MSLE Satellos Bioscience Inc. | n/m |
| CDXS Codexis, Inc. compare | n/m |
| MOLN Molecular Partners AG Sponsored ADR compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| NBP NovaBridge Biosciences compare | n/m |
| CNTN Canton Strategic Holdings, Inc. compare | 9.0× |
| MENS Jyong Biotech Ltd. compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)